Speakers

Expand/Collapse

Michael De Vivo
Vice President, Neuroscience
BioXcel Therapeutics

Day One

Wednesday 29 September, 2021

1:20 pm | Live Q&A

12:55 pm | BXCL501: Targeting Alpha2-Adrenrgic Receptors for Neuropsychiatric Symptoms

Gary Zammit
President & CEO
Clinilabs Drug Development Corporation

Day One

Wednesday 29 September, 2021

10:50 am | Live Q&A

9:35 am | Trends in Substance Use Disorder Trials

Thomas Insel
Co-founder | Chair
Humanest Care | Steinberg Institute

Day Two

Thursday 30 September, 2021

2:05 pm | Panel Discussion: How Best Can We Drive a Patient Centric Approach to Develop Efficacious & Engaging Digital Therapeutics?

Massimiliano Bianchi
Founder / President & CEO
Ulysses Neuroscience

Day One

Wednesday 29 September, 2021

12:40 pm | Translational Research in Neuropsychiatry: An Update From Ulysses Neuroscience Ltd.

1:20 pm | Live Q&A

John Kealy
CSO
Ulysses Neuroscience

Day Two

Thursday 30 September, 2021

9:10 am | Panel Discussion: Exploring Novel Electrophysiological Biomarkers of Synaptic Plasticity in Humans

Daniel Mathalon
Professor of Psychiatry and Behavioral Sciences
UCSF Weill Institute for Neurosciences

Day Two

Thursday 30 September, 2021

9:10 am | Panel Discussion: Exploring Novel Electrophysiological Biomarkers of Synaptic Plasticity in Humans

Robert Goldel
Neuroscientist & Technologist

Day Two

Thursday 30 September, 2021

2:05 pm | Panel Discussion: How Best Can We Drive a Patient Centric Approach to Develop Efficacious & Engaging Digital Therapeutics?

Jonathan Nassi
Senior Director Translational Science
Inscopix

Jonathan joined Inscopix in 2015. He received his PhD in Neuroscience from UCSD and did postdoctoral fellowships at Harvard Medical School and the Salk Institute. Jonathan is an experienced systems neurobiologist with research interests spanning neuroanatomy, in-vivo imaging, electrophysiology, optogenetics and behavioral measurements to study neural circuit function in rodents and non-human primates. At Inscopix, Jonathan oversees our translational science programs and works toward the advancement of innovative technologies that will enable tomorrow's breakthrough neuroscience discoveries and next-generation therapies for neurodegenerative and neuropsychiatric disease

Day Two

Thursday 30 September, 2021

10:35 am | A neural circuits platform to accelerate and de-risk preclinical neuropsychiatric drug development

10:50 am | Live Q&A

Jonathan Rogers
Wellcome Trust Clinical Training Fellow
UCL Division of Psychiatry

Day Two

Thursday 30 September, 2021

3:05 pm | Neuropsychiatric Implications of COVID 19

5:45 pm | Live Q&A

Judy Ashworth
Vice President Rx Strategic Services & Chief Medical Officer
Pinney Associates

Day One

Wednesday 29 September, 2021

3:25 pm | Clinical & Regulatory Challenges in Developing Psychedelics as Therapeutics

3:40 pm | Live Q&A

Judith Ford
Co-Director, Brain Imaging & EEG Lab, Professor, Department of Psychiatry, UCSF;
Senior Research Career Scientist San Francisco Veterans Affairs Medical Center

Day Two

Thursday 30 September, 2021

10:10 am | Thalamo-cortical Dysconnectivity in Schizophrenia & Youth a High Clinical Risk for Schizophrenia

Benedicto Crespo-Facorro
Director UGC HU Virgen del Rocío
CIBERSAM, Catedrático de Psiquiatría, Universidad de Sevilla

Day Two

Thursday 30 September, 2021

5:20 pm | Pharmacotranscriptomic Profiling & Molecular Mechanisms Triggered by Antipsychotics: Boosting the Search of New Drug Targets in Schizophrenia

5:45 pm | Live Q&A

Terence Kelly
CEO
Perception Neuroscience

Day One

Wednesday 29 September, 2021

10:25 am | 1PCN-101 (R-ketamine) for Treatment Resistance Depression

10:50 am | Live Q&A

Mark Varney
Chief Scientific Officer
PsychoGenics

Day One

Wednesday 29 September, 2021

5:10 pm | Live Q&A

4:30 pm | AI-driven Phenotypic Drug Discovery for CNS Indications

Stephen J. Ferrando
Director of Psychiatry at Westchester Medical Center (WMC)
Chairman of Psychiatry at New York Medical College

Day Two

Thursday 30 September, 2021

3:05 pm | Neuropsychiatric Implications of COVID 19

5:45 pm | Live Q&A

John Renger
Ph.D, Chief Scientific Officer
Cerevel Therepeutics

Day One

Wednesday 29 September, 2021

10:00 am | Development of CVL-231 for the Treatment of Psychosis

10:50 am | Live Q&A

Srinivas Rao
Co-Founder & Chief Scientific Officer
Atai Life Sciences

Day One

Wednesday 29 September, 2021

3:40 pm | Live Q&A

2:35 pm | Exploring Atai’s Unique Strategy: A Model for Innovation & Growth

Heather Dworak
Senior Director, Clinical Research
Sunovion

Day One

Wednesday 29 September, 2021

1:20 pm | Live Q&A

11:50 am | Development of SEP-363856, a TAAR1/5-HT1A Agonist for the Treatment of Schizophrenia

Amy Peters
Instructor, Department of Psychiatry Massachusetts
General Hospital & Harvard Medical School

Day Two

Thursday 30 September, 2021

5:45 pm | Live Q&A

4:05 pm | Inflammatory Mechanisms of Cognitive Dysfunction in Bipolar Disorder

Pradeep Nathan
Vice President & Head of Experimental Medicine & Professor of Neuroscience
Lundbeck

Day Two

Thursday 30 September, 2021

10:50 am | Live Q&A

9:10 am | Panel Discussion: Exploring Novel Electrophysiological Biomarkers of Synaptic Plasticity in Humans

Isabella Premoli
Imaging & Neurostimulation Specialist,
Lundbeck

Day Two

Thursday 30 September, 2021

12:50 pm | Live Q&A

12:00 pm | Implementation of a Multi-Modal Brain Stimulation Approach in Early Stage Clinical Trials

Jessica Malberg
Director, Neuroscience Development
INmune Bio

Day Two

Thursday 30 September, 2021

5:45 pm | Live Q&A

4:55 pm | TNF Inhibition as Treatment for Treatment-Resistant Depression

Daniel R Karlin
CMO,
MindMed

Day Two

Thursday 30 September, 2021

2:05 pm | Panel Discussion: How Best Can We Drive a Patient Centric Approach to Develop Efficacious & Engaging Digital Therapeutics?

Kurt Rasmussen
CSO
Delix Therapeutics

Day One

Wednesday 29 September, 2021

10:50 am | Live Q&A

9:10 am | Substance Use Disorders as a Lifecycle Play for Neuropsychiatric Drugs

Rick Doblin
Executive Director
Multidisciplinary Association for Psychedelic Studies

Day One

Wednesday 29 September, 2021

3:40 pm | Live Q&A

3:00 pm | MDMA-Assisted Therapy: With One Successful Phase 3 Study, Is FDA Approval on the Horizon?

Anindya Bhattacharya
Senior Director, Head Neuroimmunology, Neuroscience Therapeutic Area
Janssen Pharmaceutical Companies of Johnson & Johnson

Day Two

Thursday 30 September, 2021

5:45 pm | Live Q&A

4:30 pm | Dysregulated NeuroImmune Axes in Mood Disorders

Xiohai Wang
Director, Neuroscience
Merck

Day One

Wednesday 29 September, 2021

1:20 pm | Live Q&A

12:15 pm | Translational Pharmacology & Biomarker Development of the Novel α7 nAChR Positive Allosteric Modulator BNC375

Daniel C. Javitt
Director, Schizophrenia Research Program, Nathan S.Kline Institute for Psychiatric Research
Professor & Director, Division of Experimental Therapeutics, Columbia University College

Day Two

Thursday 30 September, 2021

12:50 pm | Live Q&A

11:35 am | Investigating Sensory ERP Biomarkers for Disease & Target Engagement

Jackie von Salm
Co-Founder, CSO
Psilera Bioscience

Day One

Wednesday 29 September, 2021

5:10 pm | Live Q&A

4:45 pm | Translational Research to Raise the Bar for the Development of Psychedelic-Based Medicines

Patricio O’Donnell
Executive Medical Director, Head of Neurocircuitry Modulation Biomarkers
Takeda

Day Two

Thursday 30 September, 2021